Dr Markus P Bolsinger > Dechert LLP > New York, United States > Lawyer Profile
Dechert LLP Offices
Three Bryant Park, 1095 Avenue of the Americas
NY 10036-6797
United States
- Firm Profile
- Go to...
Dr Markus P Bolsinger
Work Department
Corporate
Position
Partner
Career
Dr. Markus P. Bolsinger, co-head of Dechert’s private equity practice, structures and negotiates complex transactions – domestic and transatlantic mergers and acquisitions, leveraged buyouts, recapitalizations and going-private transactions – and advises on general corporate and corporate governance matters. Dr. Bolsinger’s experience extends across industries, including healthcare, industrial, packaging, consumer, food and beverage and restaurant sectors. His clients have included leading private equity firms, such as First Atlantic Capital, ICV Partners, J.H. Whitney & Co. and Morgan Stanley Capital Partners. In addition to his core M&A and PE experience, Dr. Bolsinger has extensive expertise in transactional risk insurance, and frequently speaks and writes on the topic in major media outlets.
Education
- Eberhard Karls University, Tübingen, J.D., 1993
- Eberhard Karls University, Tübingen, Dr. jur., 1998, magna cum laude
- The University of Chicago Law School, LL.M., 1997
Top Tier Firm Rankings
- Environment > Environment: transactional
- Dispute resolution > International arbitration
- International trade and national security > Customs, export controls and economic sanctions
- Investment fund formation and management > Mutual/registered/exchange-traded funds
- International trade and national security > Customs, export controls and economic sanctions
- Real estate > Real estate finance
- Finance > Structured finance: securitization
Firm Rankings
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Healthcare > Life sciences
- Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices
- Dispute resolution > Product liability, mass tort and class action - defense: toxic tort
- Dispute resolution > Securities litigation: defense
- Antitrust > Civil litigation/class actions: defense
- Finance > Commercial lending > Advice to direct lenders/private credit
- Dispute resolution > E-discovery
- Dispute resolution > General commercial disputes
- Dispute resolution > International litigation
- Dispute resolution > M&A litigation: defense
- Antitrust > Merger control
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Finance > Restructuring (including bankruptcy): corporate
- Tax > US taxes: non-contentious
- Finance > Capital markets: debt offerings
- Finance > Capital markets: equity offerings
- Finance > Capital markets: global offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- International trade and national security > Customs, export controls and economic sanctions
- Dispute resolution > Financial services litigation
- Finance > Fintech
- Dispute resolution > International arbitration
- Tax > International tax
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- M&A/corporate and commercial > Private equity buyouts: large deals ($500m+)
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Intellectual property > Patents: litigation (full coverage)
- Finance > Capital markets: high-yield debt offerings
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)